Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs